Candel Secures European Medicines Agency Orphan Drug Status For Brain Tumour Candidate
The European Medicines Agency (EMA) Committee for Orphan Medical Products (COMP) has issued a positive opinion on Candel Therapeutics’ (NASDAQ: CADL) application for orphan drug designation for CAN-2409 for the treatment of glioma.
